Etienne Daguidau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Etienne Daguidau has a total of 184 co-authors. Here are the top co-authors by number of shared publications:
- Philippe Saas
Université Grenoble Alpes, Inserm U 1209, CNRS UMR 5309, Institute for Advanced Biosciences (IAB), Team Translational Immunology and Immunotherapy in Chronic Disease Grenoble France
16 shared publications - Fanny Angelot-Delettre
INSERM, EFS BFC, UMR1098-RIGHT, University of Franche-Comté, Besançon, France. 1
14 shared publications - Charles-Frédéric Mantion
Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, Besançon, France
13 shared publications - Elodie Bôle-Richard
FC Innov’, Bionovéo, Besançon, France. 4
13 shared publications - Eric Deconinck
Hôpital Jean Minjoz, Besançon, France
13 shared publications - Eric Robinet
Lymphobank S.A.S.U, Besançon, France. 9
13 shared publications
Latest Publications
- Open Access
- 19 July 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (10) , 2520-2532
Eltrombopag Added to Standard Immunosuppressive Treatment as Front‐Line Therapy for Severe Aplastic Anemia: Long‐Term Outcomes of the Phase‐3 Randomized Superiority EBMT ‐ SAAWP RACE Study
The RACE study (NCT02009747) compared horse antithymocyte globulin (hATG) plus cyclosporine A (CsA) ± eltrombopag as initial immunosuppressive treatment (IST) for severe aplastic anemia. Here we report the final 2‐year analysis of this prospective randomized phase III study. One hundred ninety‐seven treatment‐naive patients were randomized to standard IST (hATG 40 mg/kg × 4 days and CsA 5 mg/kg/day; arm A; n = 101) or standard IST + eltrombopag at the dose of 150 mg/day (arm B; n = 96) from day +14 until 6 months (or 3 months, in case of complete response). The median follow‐up was 23.2 months. The 2‐year cumulative incidence of complete response was significantly superior in arm B (62.4% vs. 35.3%; p < 0.001). The 2‐year overall survival (OS) was 86% in arm A and 91% in arm B ( p = 0.081), with hazard ratio (HR), adjusted for age and disease severity, of 0.54 ( p = 0.064). The 2‐year disease‐free survival (DFS) was 56% vs. 37% (adjusted HR = 0.49; p < 0.001), while event‐free survival (EFS) was 48% vs. 32% ( p < 0.001), with adjusted HR = 0.54 ( p < 0.001), both significantly superior for arm B. The cumulative incidence of relapse was comparable in the two arms, while evolution to clinical paroxysmal nocturnal hemoglobinuria was 8% in arm A and 1% in arm B ( p = 0.041). The risk of clonal evolution remained negligible, with one patient in arm A and two in arm B developing karyotypic abnormalities. The initial hematological response benefit of eltrombopag added to IST as front‐line treatment of AA is associated with better 2‐year OS, DFS, and EFS without increased risk of secondary myeloid malignancies.
- 19 July 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (10) , 2520-2532
Open AccessEltrombopag Added to Standard Immunosuppressive Treatment as Front‐Line Therapy for Severe Aplastic Anemia: Long‐Term Outcomes of the Phase‐3 Randomized Superiority EBMT ‐ SAAWP RACE Study
The RACE study (NCT02009747) compared horse antithymocyte globulin (hATG) plus cyclosporine A (CsA) ± eltrombopag as initial immunosuppressive treatment (IST) for severe aplastic anemia. Here we report the final 2‐year analysis of this prospective randomized phase III study. One hundred ninety‐seven treatment‐naive patients were randomized to standard IST (hATG 40 mg/kg × 4 days and CsA 5 mg/kg/day; arm A; n = 101) or standard IST + eltrombopag at the dose of 150 mg/day (arm B; n = 96) from day +14 until 6 months (or 3 months, in case of complete response). The median follow‐up was 23.2 months. The 2‐year cumulative incidence of complete response was significantly superior in arm B (62.4% vs. 35.3%; p < 0.001). The 2‐year overall survival (OS) was 86% in arm A and 91% in arm B ( p = 0.081), with hazard ratio (HR), adjusted for age and disease severity, of 0.54 ( p = 0.064). The 2‐year disease‐free survival (DFS) was 56% vs. 37% (adjusted HR = 0.49; p < 0.001), while event‐free survival (EFS) was 48% vs. 32% ( p < 0.001), with adjusted HR = 0.54 ( p < 0.001), both significantly superior for arm B. The cumulative incidence of relapse was comparable in the two arms, while evolution to clinical paroxysmal nocturnal hemoglobinuria was 8% in arm A and 1% in arm B ( p = 0.041). The risk of clonal evolution remained negligible, with one patient in arm A and two in arm B developing karyotypic abnormalities. The initial hematological response benefit of eltrombopag added to IST as front‐line treatment of AA is associated with better 2‐year OS, DFS, and EFS without increased risk of secondary myeloid malignancies.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S2: Characterization of CD123 CAR-T.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S2: Characterization of CD123 CAR-T.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S1: Design of five CD123 CAR-T constructs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S1: Design of five CD123 CAR-T constructs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S4 Effect of CD123 CAR-T on humanized mouse model, NSG-SGM3.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S4 Effect of CD123 CAR-T on humanized mouse model, NSG-SGM3.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S3: Effect of CD123 CAR-T on human Hematopoietic stem cell.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S3: Effect of CD123 CAR-T on human Hematopoietic stem cell.
- 8 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Les biomarqueurs protéiques de maladie du greffon contre l’hôte : apport de la cohorte Cryostem dans la validation de biomarqueurs connus et étude de l’inhibition de ST2
Au cours des dernières décennies, le développement de biomarqueurs des complications post-allogreffe de cellules souches hématopoïétiques s'est considérablement accru. Les avancées les plus significatives ont été réalisées dans le contexte de la maladie aiguë du greffon contre l'hôte (GVHa), une complication fréquente et grave en termes de morbidité et de mortalité associées. Bien que de nombreuses variables cliniques soient connues pour prédire les résultats de la greffe, elles manquent de précision dans leurs capacités prédictives. Grâce aux progrès des technologies de la protéomique, des biomarqueurs sanguins ont été identifiés et validés dans des cohortes indépendantes afin de stratifier le risque de survenue de la GVH, de prédire la sévérité de la GVH et de prévoir le risque de mortalité liée au traitement.La protéine ST2 (suppression of tumorigenicity 2) apparaît comme le biomarqueur le plus efficace pour la GVHa. Pour la GVH chronique (GVHc), un panel combinant ST2, Osteopontin, Matrix Metalloproteinase 3 et CXCL9 a montré des propriétés pronostiques intéressantes. Ces biomarqueurs ont été mesurés dans 225 échantillons de plasma provenant de la biobanque CRYOSTEM et collectée dans les centres de greffe français entre 2012 et 2015. Les échantillons avaient été prélevés chez des patients allogreffés selon les modalités suivante : au moment de la GVHa (n = 81), au moment de la GVHc (n = 62) et chez des patients sans GVH à J100 et J365 (n = 82). Le dosage des protéines a été réalisé en ELISA avec une approche d’optimisation de la consommation de plasma. ST2 est significativement plus élevé chez les patients atteints de GVHa par rapport aux patients sans GVH, et son niveau est corrélé à la sévérité de la GVHa. Cependant, ni ce biomarqueur ni les autres biomarqueurs dans le cadre de la GVHc ne démontrent de capacité prédictive de mortalité dans cette cohorte. Ce résultat s'explique par les caractéristiques de la cohorte où la mortalité était très faible, limitant la puissance de discrimination des biomarqueurs. Par ailleurs, ST2 joue un rôle évident dans la physiopathologie de la GVHa à travers son interaction avec son ligand IL-33. En plus d'être un biomarqueur, ST2 devient aussi une cible thérapeutique potentielle. Ainsi, une approche de criblage de molécules inhibant la liaison ST2/IL-33 a été réalisée pour sélectionner trois candidats capables de réduire la gravité de la GVHa dans des modèles pré-cliniques. Nous confirmons ici l'intérêt majeur du développement des biomarqueurs dans la GVH, que ce soit pour la mise en place de stratégies préemptives/préventives individualisées ou pour permettre le développement d'approches thérapeutiques innovantes.
- 8 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Les biomarqueurs protéiques de maladie du greffon contre l’hôte : apport de la cohorte Cryostem dans la validation de biomarqueurs connus et étude de l’inhibition de ST2
Au cours des dernières décennies, le développement de biomarqueurs des complications post-allogreffe de cellules souches hématopoïétiques s'est considérablement accru. Les avancées les plus significatives ont été réalisées dans le contexte de la maladie aiguë du greffon contre l'hôte (GVHa), une complication fréquente et grave en termes de morbidité et de mortalité associées. Bien que de nombreuses variables cliniques soient connues pour prédire les résultats de la greffe, elles manquent de précision dans leurs capacités prédictives. Grâce aux progrès des technologies de la protéomique, des biomarqueurs sanguins ont été identifiés et validés dans des cohortes indépendantes afin de stratifier le risque de survenue de la GVH, de prédire la sévérité de la GVH et de prévoir le risque de mortalité liée au traitement.La protéine ST2 (suppression of tumorigenicity 2) apparaît comme le biomarqueur le plus efficace pour la GVHa. Pour la GVH chronique (GVHc), un panel combinant ST2, Osteopontin, Matrix Metalloproteinase 3 et CXCL9 a montré des propriétés pronostiques intéressantes. Ces biomarqueurs ont été mesurés dans 225 échantillons de plasma provenant de la biobanque CRYOSTEM et collectée dans les centres de greffe français entre 2012 et 2015. Les échantillons avaient été prélevés chez des patients allogreffés selon les modalités suivante : au moment de la GVHa (n = 81), au moment de la GVHc (n = 62) et chez des patients sans GVH à J100 et J365 (n = 82). Le dosage des protéines a été réalisé en ELISA avec une approche d’optimisation de la consommation de plasma. ST2 est significativement plus élevé chez les patients atteints de GVHa par rapport aux patients sans GVH, et son niveau est corrélé à la sévérité de la GVHa. Cependant, ni ce biomarqueur ni les autres biomarqueurs dans le cadre de la GVHc ne démontrent de capacité prédictive de mortalité dans cette cohorte. Ce résultat s'explique par les caractéristiques de la cohorte où la mortalité était très faible, limitant la puissance de discrimination des biomarqueurs. Par ailleurs, ST2 joue un rôle évident dans la physiopathologie de la GVHa à travers son interaction avec son ligand IL-33. En plus d'être un biomarqueur, ST2 devient aussi une cible thérapeutique potentielle. Ainsi, une approche de criblage de molécules inhibant la liaison ST2/IL-33 a été réalisée pour sélectionner trois candidats capables de réduire la gravité de la GVHa dans des modèles pré-cliniques. Nous confirmons ici l'intérêt majeur du développement des biomarqueurs dans la GVH, que ce soit pour la mise en place de stratégies préemptives/préventives individualisées ou pour permettre le développement d'approches thérapeutiques innovantes.
- 1 August 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (22) , 2461-2466
Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score–Matched Controlled Prospective Study
Cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and sometimes fatal diseases. Patients presenting with advanced-stage CTCL usually exhibit poor long-term survival outcomes. Only very few treatments have improved progression-free survival (PFS) in advanced CTCL, and no treatment has increased overall survival (OS). In 2023, the results of the CUTALLO trial supported the hypothesis that hematopoietic stem-cell transplantation (HSCT) was associated with significantly longer PFS as compared with standard-of-care treatment among advanced-stage patients although HSCT did not significantly affect OS. We provide herein the final OS data pertaining to the same patient population after a longer median follow-up of 38.9 months. Of the 99 patients included in the analysis, 55 (56%) were assigned to the HSCT group, whereas 44 (44%) were allocated to the non-HSCT group. The updated survival analysis reported that 16 of 55 patients (29%) in the HSCT group and 22 of 44 patients (50%) in the non-HSCT group died. The median OS was not reached in the HSCT group and 51.5 months (95% CI, 26.9 to 51.5) in the non-HSCT group (hazard ratio, 0.40 [95% CI, 0.20 to 0.80]). Compared with the standard of care for advanced CTCL, after extended follow-up, allogeneic HSCT was associated with significantly longer OS.
- 1 August 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (22) , 2461-2466
Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score–Matched Controlled Prospective Study
Cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and sometimes fatal diseases. Patients presenting with advanced-stage CTCL usually exhibit poor long-term survival outcomes. Only very few treatments have improved progression-free survival (PFS) in advanced CTCL, and no treatment has increased overall survival (OS). In 2023, the results of the CUTALLO trial supported the hypothesis that hematopoietic stem-cell transplantation (HSCT) was associated with significantly longer PFS as compared with standard-of-care treatment among advanced-stage patients although HSCT did not significantly affect OS. We provide herein the final OS data pertaining to the same patient population after a longer median follow-up of 38.9 months. Of the 99 patients included in the analysis, 55 (56%) were assigned to the HSCT group, whereas 44 (44%) were allocated to the non-HSCT group. The updated survival analysis reported that 16 of 55 patients (29%) in the HSCT group and 22 of 44 patients (50%) in the non-HSCT group died. The median OS was not reached in the HSCT group and 51.5 months (95% CI, 26.9 to 51.5) in the non-HSCT group (hazard ratio, 0.40 [95% CI, 0.20 to 0.80]). Compared with the standard of care for advanced CTCL, after extended follow-up, allogeneic HSCT was associated with significantly longer OS.
- Open Access
- 13 February 2025
- Published by Wiley in HemaSphere
- Vol. 9 (2) , e70088
HLA evolutionary divergence score after donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation
Donor lymphocyte infusion (DLI) prevents acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) relapses following hematopoietic stem cell transplantation. Given the life‐threatening toxicities such as graft versus host disease (GVHD), the identification of variables associated with response without toxicities is warranted. We hypothesized that HLA evolutionary divergence (HED), defined by the diversity between two given alleles of the same HLA gene, may be such a factor. A retrospective multicenter case‐control study was conducted to evaluate the outcomes of pre‐emptive (preDLI) and prophylactic DLI (proDLI) regarding their HED score, in AML or MDS patients. DLI‐treated patients were matched with controls (1:2 matched) from French transplantation centers according to hospital, hemopathy, donor type, and risk classification. In total, 201 patients were included ( N = 147 in the preDLI group, N = 54 in the proDLI group). Relapse‐free survival was significantly better in the preDLI group (hazard ratio [HR] = 0.23, 95% confidence interval [CI]: 0.14–0.55, p < 0.001) than in controls. However, this benefit was offset by a higher incidence of severe GVHD (HR = 4.88, 95% CI: 2.30–10.32, p < 0.001). HED A, B, C, DQA1, DQB1, DPB1, and DRB1 were calculated for 65 DLI‐treated patients. High‐class II HED was significantly associated with higher GVHD and relapse‐free survival (GRFS, HR = 0.33, 95% CI: 0.20–0.77, p = 0.005). Specific DQAB associations directly improved GRFS (HR = 0.23, 95% CI: 0.09–0.58, p = 0.004). In conclusion, screening the class II HED score identifies patients eligible for DLI treatment who will benefit the most from this strategy.
- 13 February 2025
- Published by Wiley in HemaSphere
- Vol. 9 (2) , e70088
Open AccessHLA evolutionary divergence score after donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation
Donor lymphocyte infusion (DLI) prevents acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) relapses following hematopoietic stem cell transplantation. Given the life‐threatening toxicities such as graft versus host disease (GVHD), the identification of variables associated with response without toxicities is warranted. We hypothesized that HLA evolutionary divergence (HED), defined by the diversity between two given alleles of the same HLA gene, may be such a factor. A retrospective multicenter case‐control study was conducted to evaluate the outcomes of pre‐emptive (preDLI) and prophylactic DLI (proDLI) regarding their HED score, in AML or MDS patients. DLI‐treated patients were matched with controls (1:2 matched) from French transplantation centers according to hospital, hemopathy, donor type, and risk classification. In total, 201 patients were included ( N = 147 in the preDLI group, N = 54 in the proDLI group). Relapse‐free survival was significantly better in the preDLI group (hazard ratio [HR] = 0.23, 95% confidence interval [CI]: 0.14–0.55, p < 0.001) than in controls. However, this benefit was offset by a higher incidence of severe GVHD (HR = 4.88, 95% CI: 2.30–10.32, p < 0.001). HED A, B, C, DQA1, DQB1, DPB1, and DRB1 were calculated for 65 DLI‐treated patients. High‐class II HED was significantly associated with higher GVHD and relapse‐free survival (GRFS, HR = 0.33, 95% CI: 0.20–0.77, p = 0.005). Specific DQAB associations directly improved GRFS (HR = 0.23, 95% CI: 0.09–0.58, p = 0.004). In conclusion, screening the class II HED score identifies patients eligible for DLI treatment who will benefit the most from this strategy.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S4 Effect of CD123 CAR-T on humanized mouse model, NSG-SGM3.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S4 Effect of CD123 CAR-T on humanized mouse model, NSG-SGM3.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S2: Characterization of CD123 CAR-T.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S2: Characterization of CD123 CAR-T.